Topological mapping of BRIL reveals a type II orientation and effects of osteogenesis imperfecta mutations on its cellular destination

Journal of Bone and Mineral Research

Volumn 29, Issue 9, 2014, Pages 2004-2016

  Patoine, Alexa ^a,b   Gaumond, Marie Hélène ^a   Jaiswal, Prashant K ^a,b   Fassier, François ^a   Rauch, Frank ^a,b   Moffatt, Pierre ^a,b  

^a SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

BRIL; cell surface protein; endoplasmic reticulum; Golgi; IFITM5; osteoblasts; osteogenesis imperfecta; palmitoylation; type II

Indexed keywords

ARGININE; BRIL PROTEIN; CYSTEINE; LEUCINE; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; IFITM5 PROTEIN, HUMAN; IFITM5 PROTEIN, MOUSE; MUTANT PROTEIN;

ARTICLE; CELL MEMBRANE; CELL MUTANT; CELL PERMEABILIZATION; COMPARATIVE STUDY; ENDOPLASMIC RETICULUM; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; OSTEOBLAST; OSTEOGENESIS IMPERFECTA; PALMITOYLATION; PROTEIN EXPRESSION; SECRETORY PATHWAY; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; COATED VESICLE; GENETICS; LIPOYLATION; METABOLISM; MOLECULAR GENETICS; MOUSE; MUTATION; PROTEIN STABILITY; PROTEIN TRANSPORT; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; CELL MEMBRANE; COP-COATED VESICLES; CYSTEINE; ENDOPLASMIC RETICULUM; HUMANS; LIPOYLATION; MEMBRANE PROTEINS; MICE; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; MUTATION; OSTEOGENESIS IMPERFECTA; PROTEIN STABILITY; PROTEIN TRANSPORT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84901270428     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2243     Document Type: Article

References (50)

1. Hickford D, Frankenberg S, Shaw G, Renfree MB,. Evolution of vertebrate interferon inducible transmembrane proteins. BMC Genomics. 2012; 13: 155.
2. Siegrist F, Ebeling M, Certa U,. The small interferon-induced transmembrane genes and proteins. J Interferon Cytokine Res. 2011; 31 (1): 183-97.
3. Zhang Z, Liu J, Li M, Yang H, Zhang C,. Evolutionary dynamics of the interferon-induced transmembrane gene family in vertebrates. PLoS One. 2012; 7 (11): e49265.
4. Sallman AM, Bringeland N, Fredriksson R, Schioth HB,. The dispanins: A novel gene family of ancient origin that contains 14 human members. PLoS One. 2012; 7 (2): e31961.
5. Moffatt P, Salois P, Gaumond MH, St-Amant N, Godin E, Lanctot C,. Engineered viruses to select genes encoding secreted and membrane-bound proteins in mammalian cells. Nucleic Acids Res. 2002; 30 (19): 4285-94.
6. Bailey CC, Huang IC, Kam C, Farzan M,. Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog. 2012; 8 (9): e1002909.
7. Kasaai B, Gaumond MH, Moffatt P,. Regulation of the bone-restricted IFITM-like (Bril) gene transcription by Sp and Gli family members and CpG methylation. J Biol Chem. 2013; 288 (19): 13278-94.
8. Hanagata N, Li X, Morita H, Takemura T, Li J, Minowa T,. Characterization of the osteoblast-specific transmembrane protein IFITM5 and analysis of IFITM5-deficient mice. J Bone Miner Metab. 2011; 29 (3): 279-90.
9. Moffatt P, Gaumond MH, Salois P, Sellin K, Bessette MC, Godin E, de Oliveira PT, Atkins GJ, Nanci A, Thomas G,. Bril: a novel bone-specific modulator of mineralization. J Bone Miner Res. 2008; 23 (9): 1497-508.
10. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, Brass AL, Ahmed AA, Chi X, Dong L, Longobardi LE, Boltz D, Kuhn JH, Elledge SJ, Bavari S, Denison MR, Choe H, Farzan M,. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011; 7 (1): e1001258.
11. Li K, Markosyan RM, Zheng YM, Golfetto O, Bungart B, Li M, Ding S, He Y, Liang C, Lee JC, Gratton E, Cohen FS, Liu SL,. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog. 2013; 9 (1): e1003124.
12. Feeley EM, Sims JS, John SP, Chin CR, Pertel T, Chen LM, Gaiha GD, Ryan BJ, Donis RO, Elledge SJ, Brass AL,. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog. 2011; 7 (10): e1002337.
13. Diamond MS, Farzan M,. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol. 2013; 13 (1): 46-57.
14. Jia R, Pan Q, Ding S, Rong L, Liu SL, Geng Y, Qiao W, Liang C,. The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. J Virol. 2012; 86 (24): 13697-707.
15. Yount JS, Moltedo B, Yang YY, Charron G, Moran TM, Lopez CB, Hang HC,. Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. Nat Chem Biol. 2010; 6 (8): 610-4.
16. Hanagata N, Li X,. Osteoblast-enriched membrane protein IFITM5 regulates the association of CD9 with an FKBP11-CD81-FPRP complex and stimulates expression of interferon-induced genes. Biochem Biophys Res Commun. 2011; 409 (3): 378-84.
17. Lange UC, Adams DJ, Lee C, Barton S, Schneider R, Bradley A, Surani MA,. Normal germ line establishment in mice carrying a deletion of the Ifitm/Fragilis gene family cluster. Mol Cell Biol. 2008; 28 (15): 4688-96.
18. Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, Lee G, Kim HN, Lee HR, Eom HH, Lee ZH, Kim OH, Park WY, Park SS, Ikegawa S, Yoo WJ, Choi IH, Kim JW,. A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet. 2012; 91 (2): 343-8.
19. Semler O, Garbes L, Keupp K, Swan D, Zimmermann K, Becker J, Iden S, Wirth B, Eysel P, Koerber F, Schoenau E, Bohlander SK, Wollnik B, Netzer C,. A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. Am J Hum Genet. 2012; 91 (2): 349-57.
20. Glorieux FH, Rauch F, Plotkin H, Ward L, Travers R, Roughley P, Lalic L, Glorieux DF, Fassier F, Bishop NJ,. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res. 2000; 15 (9): 1650-8.
21. Rauch F, Moffatt P, Cheung M, Roughley P, Lalic L, Lund AM, Ramirez N, Fahiminiya S, Majewski J, Glorieux FH,. Osteogenesis imperfecta type V: marked phenotypic variability despite the presence of the IFITM5 c.-14C > T mutation in all patients. J Med Genet. 2013; 50 (1): 21-4.
22. Takagi M, Sato S, Hara K, Tani C, Miyazaki O, Nishimura G, Hasegawa T,. A recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Med Genet A. 2013; 161 (8): 1980-2.
23. Zhang Z, Li M, He JW, Fu WZ, Zhang CQ, Zhang ZL,. Phenotype and genotype analysis of chinese patients with osteogenesis imperfecta type v. PLoS One. 2013; 8 (8): e72337.
24. Balasubramanian M, Parker MJ, Dalton A, Giunta C, Lindert U, Peres LC, Wagner BE, Arundel P, Offiah A, Bishop NJ,. Genotype-phenotype study in type V osteogenesis imperfecta. Clin Dysmorphol. 2013; 22 (3): 93-101.
25. Shapiro JR, Lietman C, Grover M, Lu JT, Nagamani SC, Dawson BC, Baldridge DM, Bainbridge MN, Cohn DH, Blazo M, Roberts TT, Brennen FS, Wu Y, Gibbs RA, Melvin P, Campeau PM, Lee BH,. Phenotypic variability of osteogenesis imperfecta type V caused by an IFITM5 mutation. J Bone Miner Res. 2013; 28 (7): 1523-30.
26. Hoyer-Kuhn H, Semler O, Garbes L, Zimmermann K, Becker J, Wollnik B, Schoenau E, Netzer C,. A non-classical IFITM5 mutation located in the coding region causes severe osteogenesis imperfecta with prenatal onset. J Bone Miner Res. 2014; 29 (6): 1387-91.
27. Farber CR, Reich A, Barnes AM, Becerra P, Rauch F, Cabral WA, Bae A, Quinlan A, Glorieux FH, Clemens TL, Marini JC,. A novel IFITM5 mutation in severe atypical osteogenesis imperfecta Type VI impairs osteoblast production of pigment epithelium-derived factor. J Bone Miner Res. 2014; 29 (6): 1402-11.
28. Guillen-Navarro E, Ballesta-Martinez MJ, Valencia M, Bueno AM, Martinez-Glez V, Lopez-Gonzalez V, Burnyte B, Utkus A, Lapunzina P, Ruiz-Perez VL,. Two mutations in IFITM5 causing distinct forms of osteogenesis imperfecta. Am J Med Genet A. 2014; 164A (5): 1136-42.
29. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig E, Adams DJ, Xavier RJ, Farzan M, Elledge SJ,. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell. 2009; 139 (7): 1243-54.
30. Yount JS, Karssemeijer RA, Hang HC,. S-palmitoylation and ubiquitination differentially regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated resistance to influenza virus. J Biol Chem. 2012; 287 (23): 19631-41.
31. Bailey CC, Kondur HR, Huang IC, Farzan M,. Interferon-induced transmembrane protein 3 is a Type II transmembrane protein. J Biol Chem. 2013; 288 (45): 32184-93.
32. Hach JC, McMichael T, Chesarino NM, Yount JS,. Palmitoylation on conserved and nonconserved cysteines of murine IFITM1 regulates its stability and anti-influenza A virus activity. J Virol. 2013; 87 (17): 9923-7.
33. John SP, Chin CR, Perreira JM, Feeley EM, Aker AM, Savidis G, Smith SE, Elia AE, Everitt AR, Vora M, Pertel T, Elledge SJ, Kellam P, Brass AL,. The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol. 2013; 87 (14): 7837-52.
34. Moffatt P, Thomas G, Sellin K, Bessette MC, Lafreniere F, Akhouayri O, St-Arnaud R, Lanctot C,. Osteocrin is a specific ligand of the natriuretic peptide clearance receptor that modulates bone growth. J Biol Chem. 2007; 282 (50): 36454-62.
35. Thomas G, Moffatt P, Salois P, Gaumond MH, Gingras R, Godin E, Miao D, Goltzman D, Lanctot C,. Osteocrin, a novel bone-specific secreted protein that modulates the osteoblast phenotype. J Biol Chem. 2003; 278 (50): 50563-71.
36. Moffatt P, Salois P, St-Amant N, Gaumond MH, Lanctot C,. Identification of a conserved cluster of skin-specific genes encoding secreted proteins. Gene. 2004; 334: 123-31.
37. Moffatt P, Smith CE, St-Arnaud R, Simmons D, Wright JT, Nanci A,. Cloning of rat amelotin and localization of the protein to the basal lamina of maturation stage ameloblasts and junctional epithelium. Biochem J. 2006; 399 (1): 37-46.
38. Small J, Rottner K, Hahne P, Anderson KI,. Visualising the actin cytoskeleton. Microsc Res Tech. 1999; 47 (1): 3-17.
39. Al-Jallad HF, Myneni VD, Piercy-Kotb SA, Chabot N, Mulani A, Keillor JW, Kaartinen MT,. Plasma membrane factor XIIIA transglutaminase activity regulates osteoblast matrix secretion and deposition by affecting microtubule dynamics. PLoS One. 2011; 6 (1): e15893.
40. Hennig D, Scales SJ, Moreau A, Murley LL, De MJ, Kreis TE,. A formiminotransferase cyclodeaminase isoform is localized to the Golgi complex and can mediate interaction of trans-Golgi network-derived vesicles with microtubules. J Biol Chem. 1998; 273 (31): 19602-1.
41. Bashour AM, Bloom GS,. 58K, a microtubule-binding Golgi protein, is a formiminotransferase cyclodeaminase. J Biol Chem. 1998; 273 (31): 19612-7.
42. Shao S, Hegde RS,. Membrane protein insertion at the endoplasmic reticulum. Annu Rev Cell Dev Biol. 2011; 27: 25-56.
43. Miller EA, Barlowe C,. Regulation of coat assembly-sorting things out at the ER. Curr Opin Cell Biol. 2010; 22 (4): 447-53.
44. Tsukamoto T, Li X, Morita H, Minowa T, Aizawa T, Hanagata N, Demura M,. Role of S-palmitoylation on IFITM5 for the interaction with FKBP11 in osteoblast cells. PLoS One. 2013; 8 (9): e75831.
45. Tang BL, Wong SH, Low SH, Hong W,. Retention of a type II surface membrane protein in the endoplasmic reticulum by the Lys-Asp-Glu-Leu sequence. J Biol Chem. 1992; 267 (10): 7072-6.
46. Rabu C, Schmid V, Schwappach B, High S,. Biogenesis of tail-anchored proteins: the beginning for the end ? J Cell Sci. 2009; 122 (Pt 20): 3605-12.
47. Hessa T, Sharma A, Mariappan M, Eshleman HD, Gutierrez E, Hegde RS,. Protein targeting and degradation are coupled for elimination of mislocalized proteins. Nature. 2011; 475 (7356): 394-7.
48. Levine CG, Mitra D, Sharma A, Smith CL, Hegde RS,. The efficiency of protein compartmentalization into the secretory pathway. Mol Biol Cell. 2005; 16 (1): 279-91.
49. Pedone K, Bernstein L, Linder M, Hepler J,. 2009 analysis of protein palmitoylation by metabolic radiolabeling methods. In:, Walker J, editor. The Protein Protocols Handbook. New York: Humana Press; p. 1623-36. 1996.
50. Rulten SL, Kinloch RA, Tateossian H, Robinson C, Gettins L, Kay JE,. The human FK506-binding proteins: characterization of human FKBP19. Mamm Genome. 2006; 17 (4): 322-31.